MARINUS PHARMACEUTICALS, INC.

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. Marinus’ product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the United States in 2022. For more information, please visit www.marinuspharma.com and follow us on Facebook, LinkedIn and X.

1. SCHEDULE 13G/A - filed by Beryl Capital Management LLC regarding MARINUS PHARMACEUTICALS, INC.May 15, 2025
2. SCHEDULE 13G/A - filed by MORGAN STANLEY regarding MARINUS PHARMACEUTICALS, INC.Mar 6, 2025
3. 15-12G filingFeb 21, 2025
4. SCHEDULE 13G/A - filed by Panacea Innovation Ltd regarding MARINUS PHARMACEUTICALS, INC.Feb 14, 2025
5. SCHEDULE 13G/A - filed by TANG CAPITAL PARTNERS LP regarding MARINUS PHARMACEUTICALS, INC.Feb 14, 2025